MA51938A1 - Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn - Google Patents

Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn

Info

Publication number
MA51938A1
MA51938A1 MA51938A MA51938A MA51938A1 MA 51938 A1 MA51938 A1 MA 51938A1 MA 51938 A MA51938 A MA 51938A MA 51938 A MA51938 A MA 51938A MA 51938 A1 MA51938 A1 MA 51938A1
Authority
MA
Morocco
Prior art keywords
compositions
methods
interfering rna
rna
patient
Prior art date
Application number
MA51938A
Other languages
English (en)
Other versions
MA51938B1 (fr
Inventor
Joel Chamberlain
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MA51938A1 publication Critical patent/MA51938A1/fr
Publication of MA51938B1 publication Critical patent/MA51938B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions et des procédés pour le traitement de troubles associés à l'épissage incorrect d'acide ribonucléique (arn), notamment des troubles caractérisés par la rétention nucléaire de transcrits d'arn contenant des régions répétées étendues de manière aberrante qui lient et séquestrent des protéines de facteur d'épissage. L'invention concerne des constructions d'arn interférant qui suppriment l'expression de transcrits d'arn contenant des régions répétées étendues, ainsi que des vecteurs viraux, tels que des vecteurs viraux adénoassociés, codant de telles molécules d'arn interférant. Par exemple, l'invention concerne des molécules d'arn interférant, telles que des constructions d'arnsi, de miarn et de sharn, qui s'hybrident à des transcrits d'arn de la protéine kinase de la dystrophie myotonique (dmpk) et atténuent l'expression de l'arn de dmpk contenant des répétitions de trinucléotides cug étendues. En utilisant les compositions et les procédés de l'invention, un patient ayant un trouble de dominance arn, tel qu'un patient humain atteint d'une dystrophie myotonique, parmi d'autres affections décrites ici, peut recevoir une construction d'arn interférant ou un vecteur la contenant afin de réduire l'apparition d'une anomalie d'épissage chez le patient, ce qui permet de traiter une étiologie sous-jacente de la maladie.
MA51938A 2018-05-15 2019-05-15 Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn MA51938B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671769P 2018-05-15 2018-05-15
PCT/US2019/032423 WO2019222354A1 (fr) 2018-05-15 2019-05-15 Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn

Publications (2)

Publication Number Publication Date
MA51938A1 true MA51938A1 (fr) 2021-11-30
MA51938B1 MA51938B1 (fr) 2022-10-31

Family

ID=68540673

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51938A MA51938B1 (fr) 2018-05-15 2019-05-15 Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn

Country Status (15)

Country Link
US (1) US20210269825A1 (fr)
EP (1) EP3793566A4 (fr)
JP (1) JP2021522836A (fr)
KR (1) KR20210010549A (fr)
CN (1) CN112469421A (fr)
AU (1) AU2019268346A1 (fr)
BR (1) BR112020023298A2 (fr)
CA (1) CA3098249A1 (fr)
CL (1) CL2020002955A1 (fr)
CO (1) CO2020015239A2 (fr)
MA (1) MA51938B1 (fr)
MX (1) MX2020012269A (fr)
PH (1) PH12020551913A1 (fr)
SG (1) SG11202011151VA (fr)
WO (1) WO2019222354A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166208B (zh) 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
TWI900553B (zh) 2020-05-13 2025-10-11 美商航海家醫療公司 Aav蛋白殼之趨性重定向
WO2023034870A2 (fr) 2021-09-01 2023-03-09 Ionis Pharmaceuticals, Inc. Composés et méthodes pour réduire l'expression de dmpk
EP4426716A1 (fr) 2021-11-02 2024-09-11 Voyager Therapeutics, Inc. Variants capsidiques de vaa et utilisations associées
WO2023196862A1 (fr) * 2022-04-06 2023-10-12 Genzyme Corporation Thérapie génique ciblée pour la dystrophie myotonique dm-1
US20250352672A1 (en) * 2022-05-13 2025-11-20 University Of Washington Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting
TW202409289A (zh) * 2022-06-27 2024-03-01 美商安斯泰來基因治療股份有限公司 用於治療肌強直性營養不良之組合物及方法
US20240384271A1 (en) * 2023-04-05 2024-11-21 Genzyme Corporation Targeted gene therapy for dm-1 myotonic dystrophy
WO2024229164A2 (fr) * 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement de troubles liés à la dystrophia myotonica protéine kinase
WO2025038795A1 (fr) * 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à la protéine kinase de la dystrophie myotonique
WO2025122536A1 (fr) * 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à la protéine kinase de la dystrophie myotonique
WO2025259747A2 (fr) * 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Compositions d'arni de protéine kinase myotonique de dystrophie (dmpk) et leurs procédés d'utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977333A (en) * 1992-02-06 1999-11-02 Massachusetts Institute Of Technology DNA sequence encoding the myotonic dystrophy gene and uses thereof
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20120322861A1 (en) * 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
EP2595663A4 (fr) * 2010-07-19 2014-03-05 Isis Pharmaceuticals Inc Modulation de l'expression de la protéine kinase de la dystrophie myotonique (dmpk)
HRP20190992T1 (hr) * 2014-12-24 2019-09-20 Uniqure Ip B.V. Suprimiranje gena za huntingtin inducirano s rnai
WO2017079291A1 (fr) * 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Composés et méthodes de modulation de c90rf72
CN115896106A (zh) * 2016-03-01 2023-04-04 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的aav载体
CN109862785B (zh) * 2016-09-30 2022-09-06 瑞泽恩制药公司 C9orf72基因座中具有六核苷酸重复扩增的非人类动物
CN112292895B (zh) * 2018-08-10 2024-06-14 富士通株式会社 一种通信方法、装置和通信系统

Also Published As

Publication number Publication date
PH12020551913A1 (en) 2021-06-14
BR112020023298A2 (pt) 2021-03-09
EP3793566A4 (fr) 2022-03-16
CN112469421A (zh) 2021-03-09
MA51938B1 (fr) 2022-10-31
WO2019222354A1 (fr) 2019-11-21
MX2020012269A (es) 2021-04-28
KR20210010549A (ko) 2021-01-27
US20210269825A1 (en) 2021-09-02
JP2021522836A (ja) 2021-09-02
SG11202011151VA (en) 2020-12-30
EP3793566A1 (fr) 2021-03-24
AU2019268346A1 (en) 2020-12-24
CO2020015239A2 (es) 2021-03-08
CA3098249A1 (fr) 2019-11-21
CL2020002955A1 (es) 2021-04-23

Similar Documents

Publication Publication Date Title
MA51938A1 (fr) Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn
Wootz et al. Alterations in the motor neuron–renshaw cell circuit in the Sod1G93A mouse model
Szczepanska-Sadowska et al. Multiple aspects of inappropriate action of renin–angiotensin, vasopressin, and oxytocin systems in neuropsychiatric and neurodegenerative diseases
MA58208B1 (fr) Acides nucléiques pour inhiber l'expression de lpa dans une cellule
Freemantle et al. Cholesterol and phospholipids in frontal cortex and synaptosomes of suicide completers: relationship with endosomal lipid trafficking genes
Zhu et al. Neutral sphingomyelinase 2 mediates oxidative stress effects on astrocyte senescence and synaptic plasticity transcripts
MA38638A1 (fr) Marqueurs pour troubles liés à la sphingomyélinase acide et leurs utilisations
Sutter et al. Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses
JP2022166193A (ja) インターフェロンレベルを低下させるのに有用な化合物
EP2970468B1 (fr) Molécules de liaison à notch2 pour le traitement de maladies respiratoires
Stasi et al. Ceruloplasmin upregulation in retina of murine and human glaucomatous eyes
Hattori et al. Increase of integrin-linked kinase activity in cultured podocytes upon stimulation with plasma from patients with recurrent FSGS
Bastick et al. Zinc supplementation prevents arsenic-induced dysregulation of ZRANB2 splice function
DE69229173T2 (de) Pla2 hemmende verbindungen
JP2025535780A (ja) アルツハイマー病においてｒｅｅｌｉｎを使用する組成物および方法
Ezomo et al. Up-regulation in the expression of renin gene by the influence of aluminium
Rostami et al. Cross-talks between the kidneys and the central nervous system in multiple sclerosis
De Gasperi et al. Peripheral myelin protein-22 is expressed in CNS myelin
Habib et al. Response of a single'mega intramuscular dose'of vitamin D on serum 25OHD and parathyroid hormone levels
WO2018024818A1 (fr) Composé pour le traitement d'une maladie associée à une dérégulation de la voie du complément alternative
Sharmin et al. How patients with neuromyelitis optica spectrum disorder accumulate disability
Farrukh et al. Membranoproliferative glomerulonephritis: A rare presentation in systemic sclerosis
Lowenthal Clinical biochemistry of epilepsy
Alkmin et al. Proteomic Profiling Reveals Region-Specific Neuroimmune and Apoptotic Signatures Induced by Bothrops jararaca Venom Toxins in the Murine Brain
Loo et al. Intranasal oxytocin mRNA-LNP can promote social behaviour and reduce pain